8.38
Schlusskurs vom Vortag:
$8.77
Offen:
$8.76
24-Stunden-Volumen:
601.60K
Relative Volume:
0.39
Marktkapitalisierung:
$451.10M
Einnahmen:
$217.25M
Nettoeinkommen (Verlust:
$-50.92M
KGV:
-8.38
EPS:
-1
Netto-Cashflow:
$-100.85M
1W Leistung:
-1.99%
1M Leistung:
+25.15%
6M Leistung:
-42.86%
1J Leistung:
-61.49%
Prothena Corporation Plc Stock (PRTA) Company Profile
Firmenname
Prothena Corporation Plc
Sektor
Branche
Telefon
011-353-1-236-2500
Adresse
77 SIR JOHN ROGERSON'S QUAY, BLOCK C, DUBLIN 2
Vergleichen Sie PRTA mit anderen Aktien
Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
---|---|---|---|---|---|---|
![]()
PRTA
Prothena Corporation Plc
|
8.38 | 459.17M | 217.25M | -50.92M | -100.85M | -1.00 |
![]()
VRTX
Vertex Pharmaceuticals Inc
|
388.94 | 99.96B | 11.39B | 3.64B | 3.50B | 13.99 |
![]()
REGN
Regeneron Pharmaceuticals Inc
|
572.38 | 60.83B | 14.21B | 4.46B | 3.56B | 39.68 |
![]()
ALNY
Alnylam Pharmaceuticals Inc
|
443.64 | 59.89B | 2.46B | -319.09M | -52.09M | -2.47 |
![]()
ARGX
Argen X Se Adr
|
677.32 | 40.47B | 3.06B | 1.28B | 447.35M | 21.30 |
![]()
ONC
Beone Medicines Ltd Adr
|
308.63 | 37.96B | 3.81B | -644.79M | -669.77M | -6.24 |
Prothena Corporation Plc Stock (PRTA) Upgrades & Downgrades
Datum | Aktion | Analytiker | Ratingänderung |
---|---|---|---|
2025-05-28 | Herabstufung | BofA Securities | Neutral → Underperform |
2025-05-27 | Herabstufung | Cantor Fitzgerald | Overweight → Neutral |
2025-05-27 | Herabstufung | Jefferies | Buy → Hold |
2025-05-27 | Herabstufung | Oppenheimer | Outperform → Perform |
2024-12-20 | Eingeleitet | Chardan Capital Markets | Buy |
2024-01-30 | Herabstufung | BofA Securities | Buy → Neutral |
2023-12-12 | Eingeleitet | Deutsche Bank | Buy |
2023-04-24 | Eingeleitet | SVB Securities | Outperform |
2023-01-27 | Eingeleitet | Piper Sandler | Overweight |
2022-11-04 | Herabstufung | RBC Capital Mkts | Outperform → Sector Perform |
2022-09-28 | Hochstufung | BofA Securities | Neutral → Buy |
2021-11-19 | Eingeleitet | JMP Securities | Mkt Outperform |
2021-06-18 | Hochstufung | BofA Securities | Underperform → Neutral |
2021-06-08 | Bestätigt | Oppenheimer | Outperform |
2021-05-26 | Eingeleitet | Citigroup | Buy |
2021-02-26 | Hochstufung | RBC Capital Mkts | Sector Perform → Outperform |
2021-02-12 | Hochstufung | Jefferies | Hold → Buy |
2021-02-02 | Hochstufung | BTIG Research | Neutral → Buy |
2020-12-07 | Eingeleitet | H.C. Wainwright | Buy |
2020-07-09 | Hochstufung | Oppenheimer | Perform → Outperform |
2019-11-19 | Hochstufung | Evercore ISI | In-line → Outperform |
2018-05-21 | Herabstufung | Barclays | Equal Weight → Underweight |
2018-04-23 | Herabstufung | Jefferies | Buy → Hold |
2018-04-05 | Bestätigt | Barclays | Overweight |
2017-11-20 | Herabstufung | Wedbush | Outperform → Neutral |
2017-09-29 | Bestätigt | BTIG Research | Buy |
2017-09-15 | Eingeleitet | RBC Capital Mkts | Outperform |
2017-08-17 | Eingeleitet | Evercore ISI | Outperform |
2017-07-11 | Eingeleitet | Jefferies | Buy |
2017-04-12 | Eingeleitet | Cantor Fitzgerald | Overweight |
2017-04-12 | Eingeleitet | Piper Jaffray | Overweight |
2017-03-02 | Eingeleitet | Instinet | Buy |
2016-12-21 | Eingeleitet | SunTrust | Buy |
2016-11-03 | Eingeleitet | Deutsche Bank | Buy |
2016-08-04 | Bestätigt | Barclays | Overweight |
2016-05-13 | Eingeleitet | Barclays | Overweight |
2016-02-19 | Bestätigt | Wedbush | Outperform |
2016-01-21 | Eingeleitet | Credit Suisse | Outperform |
Alle ansehen
Prothena Corporation Plc Aktie (PRTA) Neueste Nachrichten
Prothena Corporation plc stock outlook for YEARPortfolio Profit Report & High Win Rate Trade Alerts - Newser
Strategies to average down on Prothena Corporation plcJuly 2025 Update & Short-Term High Return Ideas - Newser
Is Prothena Corporation plc still worth holding after the dipWeekly Trend Report & Intraday High Probability Setup Alerts - Newser
How institutional ownership impacts Prothena Corporation plc stockWeekly Risk Summary & Real-Time Chart Pattern Alerts - Newser
Can swing trading help recover from Prothena Corporation plc lossesWeekly Stock Recap & Consistent Growth Equity Picks - Newser
Tick level data insight on Prothena Corporation plc volatilityBuy Signal & Free Weekly Chart Analysis and Trade Guides - Newser
Using data models to predict Prothena Corporation plc stock movement2025 Volume Leaders & AI Driven Stock Movement Reports - Newser
Earnings visualization tools for Prothena Corporation plcQuarterly Market Review & Real-Time Stock Price Movement Reports - Newser
Is Prothena Corporation plc trending in predictive chart modelsMarket Risk Analysis & Short-Term High Return Ideas - Newser
Relative strength of Prothena Corporation plc in sector analysisJuly 2025 Catalysts & Safe Capital Investment Plans - Newser
Ranking Prothena Corporation plc among high performing stocks via tools2025 Technical Overview & Stock Portfolio Risk Management - Newser
Will a bounce in Prothena Corporation plc offer an exitPortfolio Update Summary & Target Return Focused Stock Picks - Newser
Key resistance and support levels for Prothena Corporation plcPrice Action & Expert Curated Trade Ideas - Newser
Will Prothena Corporation plc see short term momentum2025 Trading Recap & Growth Focused Entry Reports - Newser
Recovery Signals Appearing in Prothena Corporation plc Charts2025 Macro Impact & High Conviction Buy Zone Picks - beatles.ru
Is Prothena Corporation plc Forming a Consolidation Base2025 Historical Comparison & Accurate Buy Signal Alerts - beatles.ru
Prothena Corporation plc Stocks Attracting Dip Buyers2025 Support & Resistance & Accurate Intraday Trade Tips - newsyoung.net
Published on: 2025-08-14 23:29:29 - sundaytimes.kr
Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes By Investing.com - Investing.com Canada
Prothena’s SWOT analysis: stock outlook shifts amid pipeline changes - Investing.com
Can trapped investors hope for a rebound in Prothena Corporation plcFree Investment Strategy With Low Risk - Newser
What MACD signals say about Prothena Corporation plcForecast Model for Intraday Buy Signals - Newser
How to escape a deep drawdown in Prothena Corporation plcFree Low Risk High Return Opportunities - Newser
How to build a dashboard for Prothena Corporation plc stockSummary of Reliable Long-Term Trade Models - Newser
Building trade automation scripts for Prothena Corporation plcBreakout Stock Opportunities with Low Drawdown - Newser
Volume spikes in Prothena Corporation plc stock – what they meanFree Safe Entry Stock Watch Suggestions - Newser
How Prothena Corporation plc stock performs during market volatilityLow Exposure Strategy with Sector Analysis - Newser
Trend Reversal Possible in Prothena Corporation plc Charts IndicateSmart Allocation Stock Pick Insights Gaining Interest - metal.it
Royal Bank Of Canada Cuts Prothena (NASDAQ:PRTA) Price Target to $10.00 - Defense World
Prothena Announces that Novo Nordisk Will Advance Coramitug (Formerly PRX004) into Phase 3 Development for ATTR Amyloidosis with Cardiomyopathy - BioSpace
Novo Nordisk Commits To Advancing Prothena Corp-Developed Drug Into Late Stage Trial: Retail Turns Hopeful - Investing.com India
Prothena (PRTA) Surges on Novo Nordisk's Phase 3 Plans for ATTR Amyloidosis Drug - GuruFocus
Prothena’s Coramitug Advances to Phase 3 with Novo Nordisk - TipRanks
Prothena Announces that Novo Nordisk Will Advance Coramitug (For - GuruFocus
Breakthrough: Novo Nordisk Takes Prothena's ATTR Drug to Final Trial Stage with $1.2B Milestone Potential - Stock Titan
Applying sector rotation models to Prothena Corporation plcFree Swing Trading Entry Point Signals - Newser
Prothena announces that Novo Nordisk will advance Coramitug into phase 3 development - MarketScreener
Prothena stock price target lowered to $10 at RBC on program discontinuation By Investing.com - Investing.com South Africa
Prothena stock price target lowered to $10 at RBC on program discontinuation - Investing.com Nigeria
PRTA: RBC Capital Maintains Rating, Lowers Price Target | PRTA S - GuruFocus
9 Analysts Assess Prothena Corp: What You Need To Know - 富途牛牛
Prothena’s Losses Grow As Revenue Drops And Programs Wind Down - Finimize
RBC Cuts Price Target on Prothena to $10 From $18, Keeps Sector Perform, Speculative Risk - MarketScreener
Prothena Corp (PRTA) Maintains 'Buy' Rating with $18 Target by C - GuruFocus
JMP reiterates Market Outperform rating on Prothena stock ahead of key data - Investing.com Nigeria
Prothena Reports Second Quarter 2025 Financial Results and Business Highlights - BioSpace
Prothena Reports Q2 2025 Financial Results and Pipeline Progress - TipRanks
Finanzdaten der Prothena Corporation Plc-Aktie (PRTA)
Umsatz
Nettogewinn
Free Cashflow
ENV
Prothena Corporation Plc-Aktie (PRTA) Insiderhandel
Insiderhandel | Beziehung | Datum | Transaktion | Kosten | #Aktien | Wert ($) | #Aktien Gesamt |
---|---|---|---|---|---|---|---|
EcoR1 Capital, LLC | 10% Owner |
May 06 '25 |
Sale |
7.64 |
1,984,053 |
15,164,712 |
5,304,596 |
EcoR1 Capital, LLC | 10% Owner |
May 05 '25 |
Sale |
8.11 |
977,693 |
7,930,166 |
7,288,649 |
SCULLY WILLIAM P | 10% Owner |
Jan 14 '25 |
Buy |
12.79 |
100,000 |
1,279,040 |
735,993 |
SCULLY WILLIAM P | 10% Owner |
Dec 18 '24 |
Buy |
13.93 |
73,436 |
1,022,670 |
1,297,693 |
SCULLY WILLIAM P | 10% Owner |
Dec 31 '24 |
Buy |
13.01 |
32,000 |
416,393 |
650,193 |
SCULLY WILLIAM P | 10% Owner |
Dec 20 '24 |
Buy |
15.91 |
2,000 |
31,813 |
618,693 |
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):